Canadian Court Blocks Generic Celebrex Launch
The Federal Court of Appeal of Canada reversed a lower court ruling that permitted Teva Pharmaceuticals’ Canadian subsidiary Novopharm from launching its version of Celebrex. The appellate court’s order prohibits regulatory approval of a generic Celebrex until Pfizer’s patents regarding the drug’s compound expire in 2014.
“Without appropriate protection of intellectual property, Pfizer and other research-based pharmaceutical companies...
To view the full article, register now.